B72.3 immunoreactivity in benign abdominal lymph nodes associated with gastrointestinal disease.

PURPOSE: Immunolocalization of the tumor-associated glycoprotein 72 antigen with the monoclonal antibody B72.3 has been used as a "cancer marker" in radioimmunoscintigraphy and radioimmunoguided surgery (RIGS). Radioimmunoscintigraphy and RIGS have been used to detect occult metastatic deposits from colorectal adenocarcinoma. It has been suggested that RIGS is superior to histologic examination in detecting lymph node metastases from colorectal cancer. To determine the specificity of immunodetection of the tumor-associated glycoprotein-72 antigen as a marker for metastatic adenocarcinoma, we studied benign intra-abdominal lymph nodes with B72.3 and an immunohistochemical technique.

METHODS: Formaldehyde-fixed, paraffin-embedded sections of 276 benign abdominal lymph nodes, resected with 35 cases of colonic adenocarcinoma and 33 cases of benign gastrointestinal disorders, were evaluated for B72.3 immunoreactivity using an avidin-biotin complex immunohistochemical technique. Lymph nodes from cases of colonic carcinoma were also studied with cytokeratin immunostaining to help eliminate occult micrometastases.

RESULTS: B72.3 immunoreactivity was seen in the germinal centers of benign lymph nodes associated with 49 percent of the cases of colonic adenocarcinoma and 12 percent of the cases of benign gastrointestinal disease.

CONCLUSIONS: B72.3 immunoreactivity can be seen in benign abdominal lymph nodes associated with gastrointestinal disease. We advise caution in the use of diagnostic techniques that equate B72.3 immunoreactivity with the presence of adenocarcinoma.